benefit only for subsets of glioma. 8 Treatment by checkpoint blockade is often accompanied by inflammation that is responsible for immune-related side effects such as dermatitis, colitis, inflammatory endocrinopathies, and even fatal cerebral edema.
8-10
Given the limited regenerative capacity of neuronal tissue, adverse events from CNS inflammation of brain parenchyma are particularly deleterious. 8 Therefore, balancing immunization activation and inflammation inhibition is a top priority during glioma immunotherapy. From this point of view, learning about immune checkpoints involved in inflammation may have implications for current checkpoint treatment.
Signaling lymphocytic activation molecule family 8 (SLAMF8, CD353) is the eighth member of SLAMF costimulatory receptors, which regulate development and function of many immune cells including T lymphocytes, B cells, neutrophils, dendritic cells, macrophages, and eosinophils. [11] [12] [13] SLAMF8 is reported to activate macrophages during inflammation, which are a major cellular component of glioma tissue. 14 Tumor-associated macrophages (TAMs) contribute to a supportive microenvironment for glioma expansion and influence the local immune and inflammation response. 15 In addition, SLAMF8 is overexpressed in autoimmune inflammation such as inflammatory bowel disease 16 and human kidney transplants, 17 suggesting SLAMF8 plays significant role in immune-related inflammation response. However, few studies have investigated the role of SLAMF8 in cancer. Accordingly, we hypothesized that SLAMF8 might be important in the immune and inflammation response of glioma. Here, we analyzed RNA sequencing (RNA-seq) data on 946 patients in Chinese Glioma Genomic Atlas (CGGA) and The Cancer Genome Atlas (TCGA) to explore the clinical and functional effects of SLAMF8, which may provide novel insights into immune checkpoints in glioma treatment.
| ME THODS

| Patient sample
A total of 946 glioma samples from CGGA and TCGA were included in our study. Samples from 310 patients with detailed clinical information were obtained from the CGGA database.
The TCGA cohort consisted of 636 patients with detailed clinical and molecular information that was downloaded from public databases (https://tcga-data.nci.nih.gov/tcga/tcgaDownload. jsp). Overall survival (OS) was estimated from date of diagnosis to death or final follow-up. Methods for sequencing, detecting IDH mutation, and MGMT promoter methylation state were described previously.
18,19
| Bioinformatics analysis
Stromal score, immune score, and glioma purity were calculated as described previously to evaluate nontumor cells with the microenvironment. 20 Microenvironment cell populations were used to quantify the absolute abundance of eight immune and two stromal cell populations from transcriptomic data as reference. 21 Pearson correlation analysis was used to obtain genes for func- Figure 1A ). These expression trends of SLAMF8 were validated in the TCGA cohort ( Figure S1A ).
The TCGA subtyping scheme classifies glioma into four subtypes. 23 We found that SLAMF8 had the highest expression in the mesenchymal subtype compared with the other subtypes in the CGGA and TCGA cohorts ( Figures 1A and S1A ). To validate this finding, we used ROC curves to test the predictive ability of SLAMF8 to determine mesenchymal subtype. The area under curve (AUC) was up to 94.2% in CGGA data ( Figure 1B ) and 93.1%
in TCGA data ( Figure S1B ), which indicated SLAMF8 was more accurate than the mesenchymal subtype determination of PD-1, TIM-3, CD44, and VIM. These results indicated that SLAMF8
was highly expressed specifically in gliomas with aggressive phenotypes.
| High SLAMF8 expression indicates unfavorable prognosis in glioma
To examine the prognostic value of SLAMF8, patients were separated based on median expression and survival curves were generated. Patients with higher SLAMF8 generally had shorter survival than those with lower SLAMF8 levels ( Figure 1C ).
Stratified survival analysis was conducted based on glioma grade.
Although tests for grade II failed to achieve statistical significance, high SLAMF8 still suggested inferior outcome in most analyses (Figures 1D-F and S1C). Similar analysis using the TCGA cohort verified that high SLAMF8 conferred poor prognosis ( Figures 1G-J and S1D). Considering the prognostic significance of SLAMF8, we F I G U R E 1 Expression profile and prognostic value of SLAMF8 in glioma. Expression of SLAMF8 differed by grade, histopathologic classification, and molecular and TCGA subtype (A). SLAMF8 was specifically enriched in mesenchymal subtype (B) in CGGA. SLAMF8 influenced glioma prognosis in CGGA (C-F) and TCGA (G-J) cohorts. SLAMF8 predicted 1-year, 3-year, and 5-year of survival in CGGA (K-M) generated ROC curves to assess the predictive value of SLAMF8 on 1-year, 3-year, and 5-year survival of the CGGA cohort. AUC was 76.7% for 1 year, 80.7% for 3 years, and 85.1% for 5 years, which was more accurate than prediction using age or IDH status
Cox regression analysis was used to test the prognostic independence of SLAMF8. Univariate and multivariate analysis indicated that SLAMF8 expression level was an independent prognostic factor in glioma (HR = 1.074, P = 0.008; Table 1 ).
SLAMF8 also independently indicated poor prognosis in the TCGA cohort (HR = 1.195, P = 0.001; Table S1 ). These findings suggested SLAMF8 had an important function in determining glioma prognosis.
| SLAMF8 has different values for predicting glioma prognosis for different molecular subtypes
The status of IDH mutations, MGMT promoter methylation, and 1p19q codeletion has significant biological and clinical value in glioma. [24] [25] [26] We investigated the prognostic role of SLAMF8 in LGG and GBM subtypes stratified by these characteristics. In LGG, no matter patients were IDH-mutant or wild-type, and increased In GBM with unmethylated MGMT promoter, no survival difference was observed between low and high SLAMF8 expression. But for MGMT-methylated GBM, the prognosis was different attributing to various SLAMF8 expression (CGGA Figure 2G ,H, TCGA Figure   S2G ,H).
| SLAMF8 is associated with chemotherapy in GBM
Radiotherapy and chemotherapy are standard adjuvant treatments for GBM. Using GBM in the CGGA cohort, we investigated the relationship between SLAMF8 and prognosis under various treatments. For patients without radiotherapy or chemotherapy, the prognosis was similar between low-and high-SLAMF8 groups. However, SLAMF8
showed prognostic significance for patients who had radiotherapy or chemotherapy ( Figure S3I-M) . We divided patients with GBM based on SLAMF8 expression. We found that in low-SLAMF8 group patients survived significantly longer with radiochemotherapy compared to patients who received radiation alone. However, this therapeutic benefit was not significant in patients with higher SLAMF8 (Figure 3A ,B).
GBMs with methylated MGMT promoter are more likely to have better prognosis and benefit from chemotherapy. 27, 28 We generated survival curves based on MGMT promoter status, treatment, and SLAMF8. For all GBMs or GBMs who received chemotherapy, only the MGMT promoter-methylated patients with lower expression of SLAMF8 had a survival advantage over the unmethylated ones.
Nevertheless, survival time of MGMT promoter-methylated patients with higher SLAMF8 was just similar to that of unmethylated patients ( Figure 3C,D) . Further analysis showed that even GBMs with methylated MGMT promoters, only patients with lower SLAMF8
benefited from chemotherapy ( Figure 3E,F) . These results indicated that high SLAMF8 may confer resistance to chemotherapy.
| SLAMF8 influenced glioma purity and local immune cell populations
To determine the influence of SLAMF8 on the tumor microenvironment, we calculated glioma immune score, stromal score, and purity in CGGA and TCGA cohorts. ( Figure 4A ). This indicated that high-SLAMF8 gliomas developed more stroma composition and recruited more mononuclear macrophages and dendritic cells leading to decreasing purity of glioma cells.
| SLAMF8 is involved in immunity and inflammation-related functions
To explore the functional implications of SLAMF8, we carried out PCA to study the transcriptomic features associated with SLAMF8. Whole transcriptome expression profiles were different between patients with tumors with high and low SLAMF8 ( Figure S4A-B These results suggested that SLAMF8 was important in immune and inflammation responses in glioma.
| SLAMF8 reinforced immunosuppression of glioma
To distinguish immune responses attributed to SLAMF8 expression, we analyzed gene sets on T cell-mediated immune response and immune response to tumor cell (Tables S2 and S3 
| High expression of SLAMF8 aggravates inflammation activity in glioma
As inflammation responses might reinforce immunosuppression and affect tumor progress, 29 we examined inflammation status for different expression levels of SLAMF8. We used metagenes to represent different types of inflammation and immune responses. 22 Genes of most clusters, HCK, LCK, MHC-I, MHC-II, STAT1, and interferon were overexpressed in high-SLAMF8 gliomas. Only IgG, which associated with activities of B lymphocytes, was enriched in low-SLAMF8 glioma (CGGA Figure 5I , TCGA Figure S5G ). Based on GO terms involved in the inflammation response, GSVA was performed to determine the relationship between SLAMF8 and inflammation more clearly. SLAMF8 had a close relationship to acute inflammation and chronic inflammation (CGGA Figure 5J , TCGA Figure S5H ). The results indicated that SLAMF8 expression was decisive for promoting the inflammation response involved in glioma.
| D ISCUSS I ON
Immunotherapy is a promising treatment with challenges. 10, 30 We found a costimulatory checkpoint molecule, SLAMF8, was important in clinical, molecular, and biological situations of glioma.
SLAMF8 was highly expressed in gliomas with malignant entities and specifically enriched in IDH wild-type and mesenchymal subtypes, which are recognized as more aggressive subtypes of glioma with enhanced immune responses. 31, 32 These findings indicated that SLAMF8 was commonly highly expressed in glioma with active immune and inflammation responses. Compared with some markers of mesenchymal subtype, SLAMF8 was more accurate in discriminating patients of mesenchymal tumor. Therefore, SLAMF8 could be an accurate molecular predictor of mesenchymal subtype and play important role in facilitating the malignant phenotype of glioma.
Previously, our team found an immune-related risk signature has important prognostic value in glioma. 33 Similarly, as an independent prognostic risk factor, the immune checkpoint SLAMF8
influenced the overall survival of glioma that higher SLAMF8 correlated with shorter survival. IDH mutation is an important F I G U R E 3 Influence of SLAMF8 on response to radiotherapy or chemotherapy. Patients receiving radiochemotherapy had better prognosis than those with radiotherapy in the low-SLAMF8 but not high-SLAMF8 group (A and B). High-SLAMF8 patients with tumors with MGMT methylation had similar survival to patients with tumors with MGMT unmethylation. Patients with tumors with low SLAMF8 survived longer than patients with GBM with MGMT unmethylation (C). Similar results for GBM patients with chemotherapy (D). For GBM with MGMT methylation and low SLAMF8, patients had better prognosis with radiochemotherapy than radiotherapy (E). Similar overall survival was seen in high-SLAMF8 group (F) F I G U R E 4 Microenvironment and biological function of SLAMF8. High SLAMF8 correlated with low purity, monocytic lineage, and myeloid dendritic cells and fibroblasts (A). DAVID analysis showed biological functions of genes correlated with SLAMF8 (B). GSEA validated biological processes related to SLAMF8 in CGGA (C-H) F I G U R E 5 Immune and inflammation response related to SLAMF8. T cell-mediated immune response and immune response to tumor cell were dissimilar in SLAMF8 low and high groups in CGGA and TCGA (A-D). Classical checkpoints correlated with SLAMF8 (E-H). Genes involved in inflammation response correlated with SLAMF8 in CGGA cohort (I). Inflammation process, including acute and chronic inflammation, was affected by SLAMF8 in CGGA (J)
(J) molecular event in glioma management that is not frequent in primary GBM. 34, 35 We found that SLAMF8 remained prognostic significant for GBMs with wild-type IDH but not mutant IDH.
IDH wild-type GBM is known to have more immune cell infiltration and enhanced immune responses than IDH-mutant ones. 
| CON CLUS ION
We examined large glioma cohorts and conducted systematic analyses in multidimensional conditions. We found that SLAMF8 was associated with malignancy progression, unfavorable prognosis, and chemotherapy resistance. As a costimulatory checkpoint, SLAMF8
has an immune function distinct from coinhibitory checkpoints, implying a promising strategy might target both coinhibitory and costimulatory checkpoints in glioma.
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